Quarter
Charts

VERTEX PHARMACEUTICALS INC / MA

VRTX

CIK 0000875320 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$3.19B
↑+9.5% +$278Mvs FY2024 (Q4)
Operating Income
$1.21B
↑+13.1% +$140Mvs FY2024 (Q4)
Net Income
$1.19B
↑+41.9% +$352Mvs FY2024 (Q4)
Gross Profit
$2.72B
↑+9.5% +$235Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
58/100
  • Profitability
    76ROIC 20.3% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.90 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    23Asset Turnover 0.50x (1.0+ = capital-efficient)
  • Growth
    48Revenue YoY +9.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 37.8% · trend +51.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project VRTX's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was -6.6%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$172.81
Total enterprise IV
$44.59B
Diluted shares
0.26B
Terminal PV
$31.42B (70% of total)
Year-5 FCF
$3.70B
YearProjected FCFDiscounted PV
+1$3.29B$2.99B
+2$3.39B$2.80B
+3$3.49B$2.62B
+4$3.59B$2.46B
+5$3.70B$2.30B
Terminal$50.60B$31.42B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$438M
investment in PP&E
Stock buybacks (TTM)
$2.02B
share count reduction
Stock-based comp (TTM)
$686M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$25.64B
everything owned
Total liabilities
$6.98B
everything owed
Stockholders' equity
$18.67B
shareholder claim
Net debt
$-4.98B
Net cash position ($4.98B)

Recent performance · 70 quarters

Revenue↑+9.5% +$278M
$3.19B
Net Income
$1.19B
Free Cash Flow↓-29.1% -$143M
$349M
Operating Margin
37.8%

Drill down

VRTX Sankey

See VERTEX PHARMACEUTICALS INC / MA's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

VRTX Charts

70 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

VRTX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics